Stereotactic radiotherapy in metastatic breast cancer

Possanzini, M.; Greco, Carlo

doi:10.1016/j.breast.2018.06.011

Cited by 17 publications

(17 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, treatment of MBC is focused on systemic therapy with the knowledge that MBC is a systemic disease. Recently, there is an increasing body of evidence to suggest local therapies to sites of metastases may improve outcomes . Early results from the SABR‐COMET study looking at stereotactic body radiotherapy (SBRT) for oligometastatic metastatic disease of solid tumors including MBC showed improvement in progression‐free survival improved from 6 to 12 months.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, there is an increasing body of evidence to suggest local therapies to sites of metastases may improve outcomes. 19 Early results from the SABR-COMET study looking at stereotactic body radiotherapy (SBRT) for oligometastatic metastatic disease of solid tumors including MBC showed improvement in progression-free survival improved from 6 to 12 months. Majority of the current evidence, however, is still limited to retrospective studies, and small patient numbers making it difficult to make definitive conclusions.…”

Section: The Role For Local Therapy (Radiation or Surgery To Sites mentioning

confidence: 99%

See 1 more Smart Citation

Research priorities in metastatic breast cancer: A James Lind Alliance Priority Setting Partnership

et al. 2020

View full text Add to dashboard Cite

Breast cancer remains the most common cancer among women, and the second most common cause of cancer death. With advances in treatment, women are living longer, in some cases many years, with metastatic breast cancer (MBC). These advances are a direct result of research, however, many studies are primarily researcher or industry led, with minimal input from patients and caregivers. The James Lind Alliance (JLA) brings patients, caregivers, and clinicians together in priority setting partnerships (PSPs) to determine key priorities in research. In this study, we utilized the JLA approach to identify unanswered questions on MBC from patient and clinical perspectives and prioritized to reach a top 10. Following the established JLA approach, MBC patients, caregivers, and health care professionals (HCPs) were surveyed to elicit their questions regarding MBC. Research questions were generated from survey responses, and following literature review to ensure the questions were currently not completely answered, an interim prioritization survey was conducted to identify a shortlist of questions taken to a final consensus meeting. One thousand, one‐hundred and ninety‐four responses were collected from 668 individuals, which were refined into 62 unique unanswered questions. The interim prioritization survey was completed by 174 individuals, and the top 27 questions were taken to a final meeting to determine by consensus the top 10. The top 10 questions cover a wide range of research questions, identified by valuable stakeholders as being priorities. This list can be used to inform prioritization and funding of future MBC research.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: The Role For Local Therapy (Radiation or Surgery To Sites mentioning

confidence: 99%

Research priorities in metastatic breast cancer: A James Lind Alliance Priority Setting Partnership

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Compared to fractionated intensity-modulated radiation therapy (IMRT), SBRT has better treatment results. 21 In one multicenter prospective study involving OMBC patients with metastatic sites including lymph nodes and lungs, better progression-free survival (PFS) and overall survival (OS) was observed. Advantage of stereotactic RT is an effective and noninvasive treatment of metastases located inside and outside the brain.…”

Section: Dovepressmentioning

confidence: 99%

“…However, the limitation is that the data were retrospective and study groups small, which might have given inaccurate results. 21,22 SBRT with dose per fraction >10 Gy causes damage to double stranded DNA in tumor cells and vascular dysfunction of the tumor. After SBRT the inflammatory reaction leads to increase of immune system cells.…”

Section: Dovepressmentioning

confidence: 99%

See 1 more Smart Citation

<p>Triple Discordances in Receptor Status During Breast Cancer Local Progression and Metastases: Case Report and Literature Review</p>

Martuszewski¹,

Paluszkiewicz²,

Nowak³

et al. 2020

OTT

View full text Add to dashboard Cite

Breast cancer is the most common female malignant neoplasm in Poland and around the world. Precise determination of tumor molecular profile allows application of appropriate anticancer therapy, increasing the chances of recovery. A 28-year-old woman detected a thickening in her left breast. Mammography showed a change measuring 60 mm (radiologically BIRADS 5). The biopsy revealed invasive ductal carcinoma, luminal subtype B, HER2 positive (cT3N1M0). Neoadjuvant chemotherapy was administered and then breast conserving surgery was performed. In postoperative histopathology cancer, biological subtype was evaluated: HER2 positive, nonluminal (ypT2ypN0cM0). Then, postoperative radiotherapy was performed. After 14 months, breast ultrasonography (US) and mammography (MGF) revealed the presence of suspicious changes (BIRADS 4). Tru-cut biopsy confirmed cancer recurrence (luminal subtype B, HER2 negative, ER negative, PgR: 10%, Ki-67: 70%). Despite implemented and modified chemotherapy regimens, local progression occurred. Genetic testing excluded BRCA gene mutation. The patient qualified for radical mastectomy modo Halsted (ypT4bN0cM0). Postoperative microscopic examination revealed triple negative breast invasive carcinoma of no special type. After 22 months, metastatic lesions in lungs and left retrosternal nodes appeared. Due to the limited possibilities of systemic treatment, the patient qualified for stereotactic radiotherapy of tumors in the lungs' and left retrosternal nodes. Advancement, histological type and molecular profile should be controlled at each stage of the disease, as they may change several times and require modification of therapy.

show abstract